Your email has been successfully added to our mailing list.

×
0.164383561643836 0.164383561643836 0.164383561643836 0.164383561643836 0.164383561643836 0.198630136986301 0.0753424657534247 0.0684931506849316
Stock impact report

Onconova Therapeutics Announces License and Collaborative Development Agreement with HanX Biopharmaceuticals for ON 123300, a Dual Inhibitor of CDK4/6 + ARK5

Onconova Therapeutics, Inc. (ONTX) 
Last onconova therapeutics, inc. earnings: 11/12 05:10 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.onconova.com/investor-overview
Company Research Source: GlobeNewswire
HanX to commercialize in Greater China: Onconova retains rights in rest of the worldHanX will fund studies towards Investigational New Drug (IND) applications in both the US and ChinaAgreement includes licensing fee, customary milestone payments and royalties on sales NEWTOWN, Pa., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), today announced the signing of a license and collaboration agreement with HanX Biopharmaceuticals, Inc., a company focused on development of novel oncology products, for the further development, registration and commercialization of ON 123300 in China. ON 123300 is a first-in-class dual inhibitor of CDK4/6 + ARK5, which is currently in advanced pre-clinical development. This compound has the potential to overcome the limitations of current generation CDK Show less Read more
Impact Snapshot
Event Time:
ONTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ONTX alerts
Opt-in for
ONTX alerts

from News Quantified
Opt-in for
ONTX alerts

from News Quantified